Shrinking lung syndrome (SLS) is not considered curable in the traditional sense, but it is treatable, and many patients experience meaningful improvement in lung function with the right therapy. This rare condition is most closely linked to systemic lupus erythematosus (SLE) and involves a progressive loss of lung volume that can cause significant breathlessness. The good news is that early recognition and aggressive treatment can slow or partially reverse the decline.
What Shrinking Lung Syndrome Actually Is
Shrinking lung syndrome is a rare complication in which the lungs progressively lose volume without any obvious blockage in the airways or scarring in the lung tissue itself. It occurs most often in people with lupus, though it has been reported in other autoimmune conditions. The hallmark finding on lung function tests is a restrictive pattern: reduced total lung capacity, reduced lung volumes overall, and a decreased ability of the lungs to transfer oxygen into the blood.
On chest X-rays, the most common finding is an elevated diaphragm on one or both sides, seen in about 69% of patients. Nearly half also show bands of collapsed lung tissue at the bases, and roughly 23% have small pleural effusions or thickening of the lining around the lungs. The lungs themselves look structurally normal, which is part of what makes the condition so puzzling and easy to miss.
Why the Lungs Shrink
The exact mechanism behind SLS is still debated, and it likely involves more than one process happening at once. The leading theories include inflammation of the pleura (the membrane surrounding the lungs) that causes pain and limits deep breathing, weakness or dysfunction of the diaphragm, and damage to the phrenic nerves that control diaphragm movement. Some patients show a combination of all three.
A case report from the American Thoracic Society described a 43-year-old man who developed severe SLS with near-total collapse of both lower lung lobes. Nerve conduction studies revealed chronic bilateral phrenic nerve paralysis, and further testing showed both muscle disease and nerve damage in the diaphragm. This highlights how multiple pathologies can overlap in a single patient, making SLS particularly challenging to pin down.
What’s notable is that 89% of SLS patients in one review had decreased maximal inspiratory and expiratory pressures, pointing to widespread respiratory muscle weakness rather than a problem with the lungs themselves. Interestingly, phrenic nerve studies were normal in 76% of the patients tested, suggesting that nerve damage alone doesn’t explain most cases.
How It Feels
The primary symptom is progressive shortness of breath with exertion. It tends to develop gradually, sometimes over weeks to months, and can range from mild to severely limiting. About 76% of patients also experience pleuritic chest pain, a sharp sensation that worsens with breathing. Because these symptoms overlap with many other lung and heart conditions, SLS is often diagnosed late, only after more common causes have been ruled out.
If you already have lupus and notice worsening breathlessness that doesn’t match your usual disease activity, SLS is worth raising with your care team. The condition won’t show up on standard imaging in the way pneumonia or a blood clot would, and it requires specific lung function testing to identify.
How Treatment Works
Treatment for SLS focuses on suppressing the underlying autoimmune process that’s driving the diaphragm weakness and pleural inflammation. The first-line approach typically involves corticosteroids to control active inflammation, often combined with immunosuppressive medications to prevent relapse and allow the steroid dose to be tapered over time.
For patients who don’t respond adequately to standard immunosuppression, biologic therapies such as rituximab have been used in refractory cases. Some clinicians have also tried theophylline, a medication that can stimulate respiratory muscles, as an add-on therapy. The evidence for these approaches comes largely from case reports and small case series rather than large clinical trials, which is typical for a condition this rare.
Treatment isn’t a quick fix. Improvement in lung volumes, when it happens, tends to be gradual over months. Some patients recover a significant portion of their lost lung capacity, while others stabilize without returning to their baseline. The degree of recovery likely depends on how much of the volume loss is driven by reversible inflammation versus permanent muscle or nerve damage.
What Recovery Looks Like
Complete resolution of SLS is possible but not guaranteed. Some patients regain near-normal lung function with sustained immunosuppressive therapy. Others improve partially, reaching a plateau where breathlessness is manageable but lung volumes remain below normal. A smaller group has persistent or progressive disease despite treatment.
The unpredictability of outcomes is one of the more frustrating aspects of SLS. Because the condition is rare, there are no large studies tracking hundreds of patients over years, so prognosis discussions rely heavily on published case series. What is clear is that earlier treatment tends to produce better results, and that untreated SLS generally continues to worsen.
Monitoring typically involves repeat lung function tests to track whether total lung capacity and other measurements are improving, stable, or declining. Chest X-rays can also show whether the diaphragm position is normalizing over time. These follow-up assessments help guide decisions about whether to continue, adjust, or escalate treatment.
Living With the Condition
SLS is a chronic condition that requires ongoing management within the broader context of lupus care. Even patients who respond well to treatment usually need long-term immunosuppression to prevent relapse. The breathlessness can affect exercise tolerance, sleep quality, and daily activities, particularly during flares or before treatment takes full effect.
Staying physically active within your limits can help maintain the respiratory muscle strength that remains. Breathing exercises designed to expand lung capacity are sometimes recommended as a supportive measure alongside medical therapy, though they aren’t a substitute for immunosuppressive treatment. The goal is to preserve as much function as possible while the underlying autoimmune process is brought under control.